01—Abstract
Summary
Summary of the 8-K filed August 3, 2022. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. reported its second quarter 2022 financial results on August 3, 2022.
The key takeaway for investors is the company's continued strong revenue performance, primarily driven by its COVID-19 vaccine sales. This filing provides a snapshot of the company's financial health and operational progress during the period, offering insights into sales trends and the underlying drivers of its financial condition. Investors should review the furnished press release for detailed financial figures and management commentary.
02—Key points
Key Highlights
- Moderna announced its financial results for the second quarter ended June 30, 2022.
- The company's performance is detailed in a press release furnished as Exhibit 99.1.
- The filing confirms that the information is furnished, not formally filed, and thus may not be subject to the same liabilities under Section 18 of the Exchange Act.
- Exhibit 99.1 contains the full press release announcing Q2 2022 financial results.
- The report includes the cover page interactive data file in Inline XBRL format.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The primary purpose of this 8-K filing is to announce and provide access to Moderna, Inc.'s financial results for the second quarter ended June 30, 2022, through a furnished press release.
Where can I find the detailed financial results for Q2 2022?
The detailed financial results are contained within the press release issued by Moderna on August 3, 2022, which is furnished as Exhibit 99.1 to this 8-K filing.
What is the significance of the information being 'furnished' rather than 'filed'?
When information is 'furnished,' it means it's provided to the SEC but is not subject to the same liability provisions under Section 18 of the Securities Exchange Act of 1934 as 'filed' information. This distinction is important for understanding the legal implications for the company.
04—Continue